Answers are grounded in this paper and cite their sources.
It is time to end the clinical focus on HDL-C and to understand how HDL's function, protein composition and size contribute to CVD risk. It will also be important to link variations in function and size to HDL-targeted therapies. Developing new metrics for quantifying HDL function, based on better understanding HDL metabolism and macrophage CEC, is critical for achieving these goals.
No takes yet. Share an insight, caveat, or question.
Ronsein et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: